WEBULL
WebtradeDownload

Recursion Pharmaceuticals (RXRX) Lands Sanofi Milestone And Trial Updates, Is The Valuation Already Too Rich?

Simply Wall St · 2d ago

Recursion Pharmaceuticals (RXRX) is back in focus after Sanofi optioned the first development candidate from their AI-enabled collaboration, triggering a US$10 million milestone payment and coinciding with fresh clinical data from two early-stage oncology programs.

Despite this fresh validation of Recursion Pharmaceuticals' AI-driven platform, the share price has been choppy, with a 7 day share price return down 13.94% and a 30 day share price return down 11.60%, even after a 20.95% 90 day rebound, and multi year total shareholder returns still deeply negative.

Compare Recursion Pharmaceuticals to other AI-focused drug discovery players by scanning curated 36 healthcare AI stocks that could also be reacting sharply to trial results and partnership news.

Bulls see fresh Sanofi validation and encouraging early oncology data as proof the Recursion Pharmaceuticals model is working. Bears point to the ongoing losses and dilutive capital raise. Which side does the current valuation lean toward?

Most Popular Narrative: 82% Overvalued

Against the last close at $3.58, the most followed narrative on Recursion Pharmaceuticals argues for a fair value of $1.97. This points to a much lower price than the market is currently assigning and sets up a very different story from recent partnership headlines.

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! 12 years later they have ZERO 0️⃣!!! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever!!! Nuff said

See why 18 investors see Recursion Pharmaceuticals as 82% overvalued.

Result: Fair Value of $1.97 (OVERVALUED)

Still, Recursion Pharmaceuticals faces clear pressure from ongoing losses and long term share price declines. Any shift in insider activity could quickly challenge this bearish narrative.

Find out about the key risks to this Recursion Pharmaceuticals narrative.

Another View: Recursion Pharmaceuticals Underpriced on Cash Flows

The most followed community narrative pins Recursion Pharmaceuticals at a fair value of $1.97, well below the recent $3.58 share price. Our DCF model paints a very different picture, with an estimated future cash flow value of $8.68, which implies the stock trades at a large discount. Which story feels more convincing when the numbers pull in opposite directions like this?

Look into how the SWS DCF model arrives at its fair value.Look into how the SWS DCF model arrives at its fair value.

RXRX Discounted Cash Flow as at Oct 2026
RXRX Discounted Cash Flow as at Oct 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 30 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around Recursion Pharmaceuticals can be confusing. Move quickly, review the underlying data, and weigh both the 2 key rewards and 3 important warning signs.

Looking For More Investment Ideas Beyond Recursion Pharmaceuticals?

Do not stop at one opportunity. Broaden your watchlist with a few focused stock ideas that match different goals, risk levels, and income needs.